ca9 af647 Search Results


ca9 af647  (R&D Systems)
90
R&D Systems ca9 af647
a-b , Representative OCR ( a ) and ECAR ( b ) tracings of MC38 tumor cell fractions with indicated injections of oligomycin (O), FCCP (F), and rotenone and antimycin A (R/AA). c-d Basal mitochondrial OCR ( c ) and cellular ECAR ( d ) of MC38 tumor fractions (n=5 mice). e , Unsupervised cluster analysis of differentially expressed metabolic mRNA transcripts of whole tumor, CD45-cancer cell, CD45+ CD11b+ F4/80hi TAM, CD45+ CD11b+ F4/80lo myeloid cell, CD45+ CD3+ CD8a+ T cell, and CD45+ CD3+ CD8a-(CD4+) T cell flow-sorted MC38 tumor populations (n=2 mice). f-g , Glucose transporter ( f ) and hexokinase ( g ) mRNA transcript levels of indicated MC38 tumor populations (n=2 mice). Dotted line approximates limit of detection. hi , Representative flow cytometry plots ( h ) and quantification ( i ) of pS6 levels in indicated MC38 tumor and spleen populations. j-k , Representative flow cytometry histograms ( j ) and quantification ( k ) of pS6 levels in cancer cells <t>(CD45-CA9+),</t> myeloid cells (CD45+ CD11b+ CD14+), T cells (CD45+ CD3+), and other immune cells (CD45+ CD3-CD14-) from patient ccRCC tumor and PBMC (n=4 patients). Each data point represents a biological replicate and error bars are SEM. a-d and f-g are representative of at least two independent experiments. P values were calculated using Welch’s 2-tailed t-test for (c-d) and Brown-Forsythe ANOVA test for (h, j). * p <0.05, ** p <0.01, *** p <0.001. ECAR: extracellular acidification rate; FCCP: Trifluoromethoxy carbonylcyanide phenylhydrazone; FMO: fluorescence minus one; MFI: median fluorescence intensity; OCR: oxygen consumption rate; PBMC: peripheral blood mononuclear cells; pS6: phosphorylated ribosomal protein S6 (Ser235/236).
Ca9 Af647, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ca9+af647/bio_rxiv__2020__08__10__238428-181-25-28?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
ca9 af647 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
camp/ll37/fall39/cathelicidin antibody [alexa fluor® 647]  (Novus Biologicals)
N/A
The CAMP/LL37/FALL39/Cathelicidin Antibody [Alexa Fluor® 647] from Novus is a CAMP/LL37/FALL39/Cathelicidin antibody to CAMP/LL37/FALL39/Cathelicidin. This antibody reacts with Human. The CAMP/LL37/FALL39/Cathelicidin antibody has been validated for the following applications: Western Blot, ELISA, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence,
   Buy from Supplier
carbonic anhydrase ix/ca9 antibody (spm314) [alexa fluor® 647]  (Novus Biologicals)
N/A
The Carbonic Anhydrase IX/CA9 Antibody (SPM314) [Alexa Fluor® 647] from Novus is a Carbonic Anhydrase IX/CA9 antibody to Carbonic Anhydrase IX/CA9. This antibody reacts with Human, Equine. The Carbonic Anhydrase IX/CA9 antibody has been validated
   Buy from Supplier
carbonic anhydrase ix/ca9 antibody [alexa fluor® 647]  (Novus Biologicals)
N/A
The Carbonic Anhydrase IX/CA9 Antibody [Alexa Fluor® 647] from Novus is a Carbonic Anhydrase IX/CA9 antibody to Carbonic Anhydrase IX/CA9. This antibody reacts with Human, Mouse, Rat, Plant. The Carbonic Anhydrase IX/CA9 antibody has been
   Buy from Supplier
carbonic anhydrase ix/ca9 antibody (spm487) [alexa fluor® 647]  (Novus Biologicals)
N/A
The Carbonic Anhydrase IX/CA9 Antibody (SPM487) [Alexa Fluor® 647] from Novus is a Carbonic Anhydrase IX/CA9 antibody to Carbonic Anhydrase IX/CA9. This antibody reacts with Human, Equine. The Carbonic Anhydrase IX/CA9 antibody has been validated
   Buy from Supplier
nedd9/casl/hef1 antibody (2g9) [alexa fluor® 647]  (Novus Biologicals)
N/A
The NEDD9/CASL/HEF1 Antibody (2G9) [Alexa Fluor® 647] from Novus is a NEDD9/CASL/HEF1 antibody to NEDD9/CASL/HEF1. This antibody reacts with Human, Mouse, Rat. The NEDD9/CASL/HEF1 antibody has been validated for the following applications: Western Blot, ELISA,
   Buy from Supplier
carbonic anhydrase ix/ca9 antibody (ca9/2993r) [alexa fluor® 647]  (Novus Biologicals)
N/A
The Carbonic Anhydrase IX/CA9 Antibody (CA9/2993R) [Alexa Fluor® 647] from Novus is a Carbonic Anhydrase IX/CA9 antibody to Carbonic Anhydrase IX/CA9. This antibody reacts with Human, Equine. The Carbonic Anhydrase IX/CA9 antibody has been validated
   Buy from Supplier
spaca9 antibody [alexa fluor® 647]  (Novus Biologicals)
N/A
The SPACA9 Antibody [Alexa Fluor® 647] from Novus is a SPACA9 antibody to SPACA9. This antibody reacts with Human. The SPACA9 antibody has been validated for the following applications: Immunoprecipitation, Western Blot (Negative).
   Buy from Supplier
carbonic anhydrase ix/ca9 antibody (66.4.c2 (pn-15)) [alexa fluor® 647]  (Novus Biologicals)
N/A
The Carbonic Anhydrase IX/CA9 Antibody (66.4.C2 (PN-15)) [Alexa Fluor® 647] from Novus is a Carbonic Anhydrase IX/CA9 antibody to Carbonic Anhydrase IX/CA9. This antibody reacts with Human, Equine. The Carbonic Anhydrase IX/CA9 antibody has been
   Buy from Supplier
carbonic anhydrase ix/ca9 antibody (ca9/781) [alexa fluor® 647]  (Novus Biologicals)
N/A
The Carbonic Anhydrase IX/CA9 Antibody (CA9/781) [Alexa Fluor® 647] from Novus is a Carbonic Anhydrase IX/CA9 antibody to Carbonic Anhydrase IX/CA9. This antibody reacts with Human, Equine. The Carbonic Anhydrase IX/CA9 antibody has been validated
   Buy from Supplier
carbonic anhydrase ix/ca9 antibody (pn-15) [alexa fluor® 647]  (Novus Biologicals)
N/A
The Carbonic Anhydrase IX/CA9 Antibody (PN-15) [Alexa Fluor® 647] from Novus is a Carbonic Anhydrase IX/CA9 antibody to Carbonic Anhydrase IX/CA9. This antibody reacts with Human, Equine. The Carbonic Anhydrase IX/CA9 antibody has been validated
   Buy from Supplier

Image Search Results


a-b , Representative OCR ( a ) and ECAR ( b ) tracings of MC38 tumor cell fractions with indicated injections of oligomycin (O), FCCP (F), and rotenone and antimycin A (R/AA). c-d Basal mitochondrial OCR ( c ) and cellular ECAR ( d ) of MC38 tumor fractions (n=5 mice). e , Unsupervised cluster analysis of differentially expressed metabolic mRNA transcripts of whole tumor, CD45-cancer cell, CD45+ CD11b+ F4/80hi TAM, CD45+ CD11b+ F4/80lo myeloid cell, CD45+ CD3+ CD8a+ T cell, and CD45+ CD3+ CD8a-(CD4+) T cell flow-sorted MC38 tumor populations (n=2 mice). f-g , Glucose transporter ( f ) and hexokinase ( g ) mRNA transcript levels of indicated MC38 tumor populations (n=2 mice). Dotted line approximates limit of detection. hi , Representative flow cytometry plots ( h ) and quantification ( i ) of pS6 levels in indicated MC38 tumor and spleen populations. j-k , Representative flow cytometry histograms ( j ) and quantification ( k ) of pS6 levels in cancer cells (CD45-CA9+), myeloid cells (CD45+ CD11b+ CD14+), T cells (CD45+ CD3+), and other immune cells (CD45+ CD3-CD14-) from patient ccRCC tumor and PBMC (n=4 patients). Each data point represents a biological replicate and error bars are SEM. a-d and f-g are representative of at least two independent experiments. P values were calculated using Welch’s 2-tailed t-test for (c-d) and Brown-Forsythe ANOVA test for (h, j). * p <0.05, ** p <0.01, *** p <0.001. ECAR: extracellular acidification rate; FCCP: Trifluoromethoxy carbonylcyanide phenylhydrazone; FMO: fluorescence minus one; MFI: median fluorescence intensity; OCR: oxygen consumption rate; PBMC: peripheral blood mononuclear cells; pS6: phosphorylated ribosomal protein S6 (Ser235/236).

Journal: bioRxiv

Article Title: Cell Programmed Nutrient Partitioning in the Tumor Microenvironment

doi: 10.1101/2020.08.10.238428

Figure Lengend Snippet: a-b , Representative OCR ( a ) and ECAR ( b ) tracings of MC38 tumor cell fractions with indicated injections of oligomycin (O), FCCP (F), and rotenone and antimycin A (R/AA). c-d Basal mitochondrial OCR ( c ) and cellular ECAR ( d ) of MC38 tumor fractions (n=5 mice). e , Unsupervised cluster analysis of differentially expressed metabolic mRNA transcripts of whole tumor, CD45-cancer cell, CD45+ CD11b+ F4/80hi TAM, CD45+ CD11b+ F4/80lo myeloid cell, CD45+ CD3+ CD8a+ T cell, and CD45+ CD3+ CD8a-(CD4+) T cell flow-sorted MC38 tumor populations (n=2 mice). f-g , Glucose transporter ( f ) and hexokinase ( g ) mRNA transcript levels of indicated MC38 tumor populations (n=2 mice). Dotted line approximates limit of detection. hi , Representative flow cytometry plots ( h ) and quantification ( i ) of pS6 levels in indicated MC38 tumor and spleen populations. j-k , Representative flow cytometry histograms ( j ) and quantification ( k ) of pS6 levels in cancer cells (CD45-CA9+), myeloid cells (CD45+ CD11b+ CD14+), T cells (CD45+ CD3+), and other immune cells (CD45+ CD3-CD14-) from patient ccRCC tumor and PBMC (n=4 patients). Each data point represents a biological replicate and error bars are SEM. a-d and f-g are representative of at least two independent experiments. P values were calculated using Welch’s 2-tailed t-test for (c-d) and Brown-Forsythe ANOVA test for (h, j). * p <0.05, ** p <0.01, *** p <0.001. ECAR: extracellular acidification rate; FCCP: Trifluoromethoxy carbonylcyanide phenylhydrazone; FMO: fluorescence minus one; MFI: median fluorescence intensity; OCR: oxygen consumption rate; PBMC: peripheral blood mononuclear cells; pS6: phosphorylated ribosomal protein S6 (Ser235/236).

Article Snippet: The antihuman antibodies used were: CD45 BV421 (HI30, BioLegend 304032), CD3 APC (UCHT1, BioLegend 300439), CD11b PerCP-Cy5.5 (ICRF44, BioLegend 301328), CD14 BV510 (M5E2, BioLegend 301842), CA9 AF647 (303123, R&D Systems FAB2188R-100UG), Human Fc Block (BD 564220).

Techniques: Flow Cytometry, Fluorescence